PET Imaging of Breast Cancer

Lebron, Lizza; Greenspan, Daniel S.; Pandit‐Taskar, Neeta

doi:10.1016/j.cpet.2014.12.004

Cited by 22 publications

(9 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of 18 F-FDG PET/CT in the evaluation of newly diagnosed breast cancer is controversial 1–3 . According to the current literature and the National Comprehensive Cancer Network guidelines, 18 F-FDG PET/CT is not routinely applied for the early diagnosis of breast cancer 4 .…”

Section: Introductionmentioning

confidence: 99%

68Ga-FAPI Versus 18F-FDG PET/CT in Evaluating Newly Diagnosed Breast Cancer Patients

et al. 2023

View full text Add to dashboard Cite

Purpose This study aimed to compare the performance of 68Ga-FAPI and 18F-FDG PET/CT in the evaluation of patients with newly diagnosed breast cancer. Methods Thirty-four women with newly diagnosed breast cancer who underwent both 68Ga-FAPI and 18F-FDG PET/CT within 1 week were prospectively included in the study. The imaging characteristics of primary lesions, diagnostic efficiency of lymph node metastasis (LNM), and accuracy of N stage evaluation between 2 PET/CTs were compared. Results 68Ga-FAPI showed higher SUVmax (11.06 ± 5.48 vs 8.33 ± 6.07, P = 0.02) and tumor-to-background ratio (15.32 ± 10.33 vs 8.25 ± 5.51, P < 0.001) than 18F-FDG in primary tumors. 68Ga-FAPI SUVmax was positively correlated with the pathological grade of the primary lesions and the final stage of the patients (P < 0.001). The specificity and accuracy of 68Ga-FAPI was higher than that of 18F-FDG in the diagnosis of LNMs on patient-based and lesion-based analysis (P < 0.001). The accuracy for the evaluation of N stage and N0 axillar status was 91.2% (31/34) and 85.7% (12/14) for 68Ga-FAPI, and 73.5% (25/34) and 42.9% (6/14) for 18F-FDG, respectively. Conclusions The 68Ga-FAPI SUVmax was positively correlated with the pathological grade of the primary lesions and the final stage of the patients. 68Ga-FAPI PET/CT has higher accuracy than 18F-FDG in the evaluation of N stage, especially N0 axillar status, which is helpful to improve the treatment strategy for breast cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

68Ga-FAPI Versus 18F-FDG PET/CT in Evaluating Newly Diagnosed Breast Cancer Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Radiotracers with affinity for progesterone receptors (FFNP), HER2 receptors (89-zirconium-, 64-copper-, or 68-gallium-trastuzumab), and androgen receptors (FDHT) to non-invasively identified specific breast tumor subtypes and treatment response are promising in early pilot studies [ 124 – 130 ]. 18F-FFNP was shown to provide information of progesterone receptor expression in primary and metastatic breast cancer [ 127 ]. Change in 18F-FFNP tumor uptake after estradiol challenge was also highly predictive of response to endocrine therapy for women with HR-positive breast cancer; therefore, this PET radiotracer has potential to identify patients who may respond well to endocrine therapy [ 126 ].…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions

Yoon,

Bazan

2024

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose We examine the potential for curative approaches among metastatic breast cancer (MBC) patients by exploring the recent literature on local ablative therapies like surgery and stereotactic body radiation therapy (SBRT) in patients with oligometastatic (OM) breast cancer. We also cover therapies for MBC patients with oligoprogressive (OP) disease. Key Findings Surgery and SBRT have been studied for OM and OP breast cancer, mainly in retrospective or non-randomized trials. While many studies demonstrated favorable results, a cooperative study and single-institution trial found no support for surgery/SBRT in OM and OP cases, respectively. Conclusion While there is interest in applying local therapies to OM and OP breast cancer, the current randomized data does not back the routine use of surgery or SBRT, particularly when considering the potential for treatment-related toxicities. Future research should refine patient selection through advanced imaging and possibly explore these therapies specifically in patients with hormone receptor-positive or HER2-positive disease.

show abstract

“…They are considered important biomarkers to determine prognosis and predict the benefit of endocrine therapies in breast cancer patients [80,81]. Tumors with high levels of ER and PR are less aggressive and more indolent than negative tumors receptor [7].…”

Section: Hormone Receptorsmentioning

confidence: 99%

“…Clinical studies have revealed that [ 18 F]FES is useful to detect positive lesions both in primary and metastatic breast cancer and in predicting response to anti-ER treatments with a good sensitivity (69–100%) and high specificity (80–100%) [9,10,11,12]. Therefore, [ 18 F]FES-PET is an appropriate imaging tool for the diagnosis, staging, and post-therapeutic evaluation of patients with ER+ breast cancer [7]. It has been reported that this tracer shows greater benefits than [ 18 F]-FDG-PET to distinguish flare reaction from a real disease progression [13].…”

Section: Hormone Receptorsmentioning

confidence: 99%

Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer

Salvatore

Caprio

Hill

et al. 2019

Cancers

View full text Add to dashboard Cite

Breast cancer remains the most frequent cancer in women with different patterns of disease progression and response to treatments. The identification of specific biomarkers for different breast cancer subtypes has allowed the development of novel targeting agents for imaging and therapy. To date, patient management depends on immunohistochemistry analysis of receptor status on bioptic samples. This approach is too invasive, and in some cases, not entirely representative of the disease. Nuclear imaging using receptor tracers may provide whole-body information and detect any changes of receptor expression during disease progression. Therefore, imaging is useful to guide clinicians to select the best treatments for each patient and to evaluate early response thus reducing unnecessary therapies. In this review, we focused on the development of novel tracers that are ongoing in preclinical and/or clinical studies as promising tools to lead treatment decisions for breast cancer management.

show abstract

PET Imaging of Breast Cancer

Cited by 22 publications

References 97 publications

68Ga-FAPI Versus 18F-FDG PET/CT in Evaluating Newly Diagnosed Breast Cancer Patients

68Ga-FAPI Versus 18F-FDG PET/CT in Evaluating Newly Diagnosed Breast Cancer Patients

Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions

Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer

Contact Info

Product

Resources

About